Aspire IRB Joins SCRS as a Global Impact Partner

PRESS RELEASE

Denise Davis, Executive Coordinator
Society for Clinical Research Sites
410.696.5080
denise.davis@myscrs.org

For Immediate Release
Society for Clinical Research Sites Receives Unprecedented Response from Industry Stakeholders to Support Sites by Joining Corporate Partnership Program
Acurian, Amgen, Aspire IRB, AstraZeneca, Bio-Optronics, Inc., CFS Clinical, Clinical Site Services, DAC Patient Recruitment Services, Eli Lilly, ePharmaSolutions, PPD, and Roche are among the founding supporters.

Rockville, MD, June 20, 2013: The Society for Clinical Research Sites (SCRS) is proud to announce the launch of the Global Impact Partnership (GIP) Program. In just over a month, twelve organizations have joined SCRS’ commitment to research site’s success. SCRS Global Impact Partners will provide ongoing development, feedback, and support of industry initiatives designed to include and improve the voice of clinical research sites. In just seven months since its announcement, SCRS has grown its global membership to represent 1,300 sites in 12 countries. Within a constantly evolving industry, the Global Impact Partnership Board will work in tandem with SCRS’ Leadership Council to identify the work streams most significant to the success of research sites across the world. Each GIP member will appoint one executive level team member to represent their organization and each organization has made a two year commitment to SCRS.
 
The founding GIP industry partners include:
Amgen, AstraZeneca, Eli Lilly, PPD, and Roche

While GIP professional partners include:
Acurian, Aspire IRB, Bio-Optronics, Inc., CFS Clinical, Clinical Site Services, DAC Patient Recruitment Services, and ePharmaSolutions.

More industry GIP members will be announced in the months ahead as are invited. However, the supplier seats are limited to only 12 organizations. The first meeting of the GIP Board will be held at this year’s Site Solutions Summit in Amelia Island, FL. The GIP Board will work towards industry changes from operational management, to contracts, to subject retention, and more. Their collaboration will SCRS continue throughout the year.

SCRS President, Christine Pierre states that "The response we have received from sites joining at such a rapid rate was not a surprise; sites are committed to the industry and to our volunteers. However, the response our community of sites has received from industry has affirmed that the mission of SCRS to represent the global site community and ensure our voice is heard was long overdue, and they want to be a part of the advancement of SCRS. It has long been my position that success in the clinical research ecosystem is dependent on the foundation of a strong site base. Without sites there are no subjects, without subjects there are no new treatments. Critical success factors are different around the globe, and we look forward to working with our GIPs, Leadership Council and SCRS members to ensure all sites succeed.”

About SCRS
SCRS is a trade organization representing global clinical research sites representing 1,300 sites in 12 countries in just seven months of its launch. SCRS’ mission is to unify and amplify the voice of the global clinical research site community. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will also benefit from membership. Visit www.myscrs.org.

GREATER SAN DIEGO ACRP CHAPTER -NETWORKING

Aspire hopes to see you at the following event: Interested in expanding your professional network or fostering new professional connections in a casually-sophisticated ambiance? Join us for great food, drinks, and networking with San Diego’s Clinical Research Professionals! Thursday, June 27, 2013 5:30 pm - 8:30 pm SEASONS 52 4505 La Jolla Village Drive Suite C-1 La Jolla, CA 92122 Free for ACRP Members $10 at the door for Non Members MANDATORY RSVP BY JUNE 20. Link to RSVP is located on our chapter website. http://www.acrpnet.org/GetInfoFor/USChapters/GreaterSanDiego.aspx

Touch A Truck is here again! Join us June 8th at Qualcomm San Diego

Can you help us spread the word about Touch A Truck San Diego? We have event flyers and exhibitor invites to hand out. Email us for info on how to get some in your hands, . info@maxsringoffire.org or download the attached PDF. http://ow.ly/d/1eeu

Deviations and the Regulations — What Matters Most? - Tuesday, May 21, 2013 at 12:00 PM EDT on Webvent.tv

Aspire IRBs COO, Charlotte Stewart and Lead Medical Reviewer, Dr. Susan Abramson are presenting next month for the GCP Webinar series hosted by SCRS!  Don't miss out...
Deviations and the Regulations — What Matters Most? - Tuesday, May 21, 2013 at 12:00 PM EDT on Webvent.tv

REGARDING WAIVERS OF INFORMED CONSENT

We occasionally find there is confusion about waivers of informed consent.  That may be because different regulations and guidances govern different situations.

Waiver requirements differ depending on whether or not FDA regulates the research.  Also, there are different requirements for waiving (or altering) informed consent overall, versus waiving the requirement to document written informed consent.

So, when applying for a consent waiver, determine first:  is the research FDA regulated, and is an overall waiver, or just a waiver of getting written consent, what is required?

Please note that any waivers or alteration of consent, or its documentation, are, in the end, the IRB’s decision, not the investigator’s or the sponsor’s.  Aspire will work with its clients to be sure that the decisions and their documentation are appropriate.

Most of the research submitted to Aspire is FDA-regulated, so let’s start there.

For waivers of informed consent overall, in FDA-regulated research:  FDA allows full-on waivers of informed consent only in limited situations.  A long list of requirements must be met, but the “gatekeeper” requirement is that the research must be emergency research for life-threatening situations.  See 21 CFR 50.24 for the applicable regulations.  If your research is FDA-regulated (that is, involving a drug, device, or other substance regulated by FDA), and it is not emergency research, you need to get informed consent, and follow the required elements of informed consent.

A significant exception to this is in vitro diagnostic device research that uses archived, leftover human specimens obtained during the course of other research or routine clinical care.  The regulations do not say that consent may be waived in such cases, but, in a 2006 guidance document, the FDA said it would use its “enforcement discretion” if seven specific criteria are met and the IRB documents that they are met.   The criteria, paraphrased here, are IRB review of the study, plus these six: a) the device must be IDE-exempt; b) the specimens must be leftover from routine care, analysis, or other research, and would have otherwise been discarded; c) the specimens are not individually identifiable by the investigators “or any other individuals associated with the investigation or the sponsor”; d) clinical information may accompany the specimens as long as it does not make the specimen source identifiable; e) the individuals caring for the patients supplying the specimens “are different from and do not share information about the patient with those conducting the investigation”; and f) the specimens are provided “without identifiers and the supplier of the specimens has established policies and procedures to prevent the release of personal information”  (emphasis by Aspire).  ALL of these must be met.  The last one, item f) bears particular emphasis:  there must be a process in place at the specimen source (e.g., tissue bank) to protect personal information, and the IRB must be satisfied that the process is in place.

Also, for research involving children (minors), FDA regulations provide, in 21 CFR 50.55, for waiver of assent under certain conditions:  a) the child is unable to provide assent, OR b) (paraphrasing here) the prospect of direct benefit is important and available only in the study, OR c) the research is minimal risk AND the waiver will not harm the children’s rights or welfare AND the study could not be “practicably” carried out without the waiver AND “whenever appropriate,” the subjects will be given pertinent information after participation in the study is over.  These criteria also apply to alteration of the assent process.

[Note that “practicably”:  Many have complained about the use of that word.  Interpreting it in the context of the regs involves a judgment call by the IRB.]

FDA does allow that the requirement to document informed consent may be waived (21 CFR 59.109) if EITHER the research is emergency research, OR “the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context.”  At least, these are easier to remember, but if they apply, informed consent still must be obtained—you just don’t need an ICF.  In this case, the IRB will decide whether the exemption applies to all subjects in the study, or just some, and the IRB may require the investigator to provide subjects with a written statement about the research.

For research not regulated by FDA, the OHRP regulations in 45 CFR 46 are the most applicable.  In general, these apply to federally-funded research, but under the rubric of the Common Rule, Aspire considers them to apply to non-FDA-regulated human subject research in general when it comes to questions of waiving consent.  Here:

The requirement to obtain informed consent may be waived, or the elements altered, for non-FDA-regulated research, if ALL of the following are true (45 CFR 46.116(d)):  the research involves no more than minimal risk to subjects AND the waiver or alteration will not adversely affect the subjects’ rights or welfare AND the research could not be “practicably” [there’s that word again] carried out without the waiver or alteration AND subjects will be given pertinent information after participation “whenever appropriate.”  Sound familiar?  Note this overlaps with FDA’s requirements ONLY with regard to waiver of assent for children.

Finally, the requirement to document informed consent may be waived for non-FDA-regulated research (45 CFR 46.117(c)) if EITHER “the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context” [consonant with FDA on this point] OR the consent form would be the only record linking the subject and the research, and the principal risk would be harm from a breach of confidentiality.  Note that, in the latter case, “each subject will be asked (emphasis ours) whether the subject wants” such documentation, “and the subjects (sic) wishes will govern.”

It’s not TOO complicated, but it can get confused.  When requesting a waiver of some sorts regarding consent, walk through this process.  Ask Aspire for help if you need.

Oh, and note:  the above doesn’t have anything to do with HIPAA waivers.  That’s a different topic, for another time.

Aspire IRB supports Max's Ring of Fire

Max's Ring of Fire (MROF), a 501(c)3 tax-exempt public charity, is a pediatric cancer fundraising and advocacy organization that supports innovative pediatric cancer research and clinical trials. We are dedicated to funding practical, relevant Phase I and II clinical trials which are based on research from the University of Vermont, University of Texas/M.D. Anderson Cancer Center, University of Hawaii, UCSD, the Van Andel Institute, among others.

We also focus on speed, by helping to bring new therapies to the bedside now for the patients that need them most - those with advanced relapsed or refractory neuroblastoma. These are the hard cases that most oncology research frequently overlooks - yet it is these difficult cases that likely hold the key to finding the answer to cancer.

100% of every donated dollar is guaranteed to fund meaningful neuroblastoma research and clinical trials.

1 incredible day (9/29)
2 amazing events (Max Run followed by Touch A Truck)
1 great cause (childhood cancer)

Tickets / Race registration both live NOW!
Touch A Truck: https://mrof.webconnex.com/tat12
Max Run: https://mrof.webconnex.com/MaxRun

INTO THE BRAVE NEW WORLD OF INTERNET RESEARCH

We at Aspire are just beginning to see submissions for research done via the internet.  It’s an area we are still learning ourselves, and for which some of our processes are in development.  At this juncture, we would make only a few comments about internet-based research.  From our vantage point, the most salient concerns so far appear to be over consent and confidentiality.

Regarding consent, the existing regulations still apply (at least, pending any relevant revisions to the Common Rule, which will not be in place for at least a little while yet).  Absent the appropriate waivers, consent processes and documents (provided online) still must include all the required elements of informed consent.  Depending on the case, obtaining documentation—especially, an appropriate signature—of informed consent may pose a challenge.

Regarding confidentiality, we are reminded that the internet is not a secure medium.  Transmission of data may be vulnerable, and precautions must be in place to protect from hackers and other workers of maleficence, spyware, and the like.  Aspire will need to see a description of the processes in place to protect confidentiality.  As part of our review, we envision routinely asking our in-house IT professional to review and assess these processes.

A recent PRIM&R webinar on the subject suggested the following practices for describing confidentiality protections; anticipate that Aspire will ask for these with any submission for internet-based research:

·       Explain how data are transmitted.  Is a survey host used?  Will the host retain identifiable data, and will they be encrypted?

·       Explain how data are maintained—in individually identifiable form, aggregate form, anonymized, etc?  These points become especially critical if data sharing is involved.

·       Explain the data security plan.  The webinar cited the Harvard security plan (security.harvard.edu) as an example.

·       Do not guarantee absolute confidentiality—in fact, point out to subjects that such a guarantee cannot be made.

·       If aggregated anonymized data will be made publicly available, consider whether subjects could be (re)identified.  In general, keeping data de-identified or anonymized is a concern for any internet-based human subject research.

Also, as for any human subject research it reviews, Aspire will want to understand who has access to what data and how that access is protected or restricted (passwords and the like).

We are always committed to service, and for any internet-based research we review, we will work with our clients to be sure that we have and understand the appropriate information.  We will remain responsive and, to the degree permitted by law and regulation, flexible as we handle these requests.  Please don’t hesitate to call us to discuss.